PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
-30.37%
Negative gross profit growth while Biotechnology median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-24.83%
Negative EBIT growth while Biotechnology median is 0.72%. Seth Klarman would check if external or internal factors caused the decline.
-24.83%
Negative operating income growth while Biotechnology median is 1.69%. Seth Klarman would check if structural or cyclical issues are at play.
-17.79%
Negative net income growth while Biotechnology median is 1.19%. Seth Klarman would investigate factors dragging net income down.
-12.12%
Negative EPS growth while Biotechnology median is 4.33%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-9.09%
Negative diluted EPS growth while Biotechnology median is 4.26%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
5.06%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
6.04%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-120.47%
Negative OCF growth while Biotechnology median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-120.93%
Negative FCF growth while Biotechnology median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-252.09%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
90.56%
OCF/share CAGR of 90.56% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
77.71%
3Y OCF/share growth of 77.71% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
99.67%
Net income/share CAGR of 99.67% while Biotechnology median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
85.97%
Net income/share CAGR of 85.97% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
69.72%
3Y net income/share CAGR of 69.72% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
173.45%
Equity/share CAGR of 173.45% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-62.01%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
56.61%
3Y equity/share CAGR of 56.61% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-13.24%
Negative BV/share change while Biotechnology median is -8.90%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-1.77%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
45.24%
R&D growth of 45.24% while Biotechnology median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-4.95%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.